Company: OPGN
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001829126-25-009312
Chunk: 17

Company: OPGEN INC
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 17
---
     (Loss) earnings per share
     
    $
    (0.06
    )
     
    $
    1.43

    $
    (0.06
    )
     
    $
    1.35

    Basic

    Diluted

    Nine months ended  September 30,

    Nine months ended September 30,

    2025

    2024

    2025

    2024

    Net income
     
    $
    2,493,129

    $
    7,642,696

    $
    2,493,129

    $
    7,642,696

    Net income allocated to preferred stock

    (15,034
    )

    (519,161
    )

    -

    -

    Net income available to common stockholders
     
    $
    2,478,095

    $
    7,123,535

    $
    2,493,129

    $
    7,642,696

    Basic weighted average shares outstanding

    10,071,218

    2,837,744

    10,071,218

    2,837,744

    Dilutive effect of preferred stock 

    61,100

    733,761

    Dilutive effect of restricted stock units

    62,983

    -

    Dilutive weighted average shares outstanding

    10,195,301

    3,571,505

    Earnings per share
     
    $
    0.25

    $
    2.51

    $
    0.24

    $
    2.14

None of the potential dilutive securities had a dilutive impact during the three months ended September 30, 2025 due to the Company’s net loss.

The number of anti-dilutive
shares, consisting of common shares underlying (i) preferred stock, (ii) common stock options, (iii) restricted stock units and (iv)
stock purchase warrants, which have been excluded from the computation of diluted income per share, was 1.4
million shares and 1.1 million shares for the three and nine months ended September 30, 2025, respectively.

The number of anti-dilutive shares for both the three and nine months ended September 30, 2024, consisting of common shares underlying (i) preferred stock